Genentech Halts Phase 3 Trials Testing Crenezumab for Early Alzheimer’s Disease

Genentech Halts Phase 3 Trials Testing Crenezumab for Early Alzheimer’s Disease
Two Phase 3 trials — CREAD 1 and CREAD 2 — evaluating crenezumab as a therapy for early Alzheimer’s disease have been discontinued, Genentech announced. The decision was based on an interim analysis by an independent data monitoring committee that ruled that crenezumab was unlikely to meet its primary goal of halting dementia progression as measured by the Clinical Dementia Rating-Sum of Boxes Score. The overall safety profile of crenezumab was similar to that seen in previous trials, without any new safety signals. Findings from the Phase 3 trials will help design and rethink strategies for future trials and research. Genentech will present these clinical results at upcoming medical conferences. “While the results with crenezumab are disappointing, they meaningfully contribute to our understanding of Alzheimer’s disease,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech, said in a press release. Crenezumab is an investigational monoclonal antibody first discovered by AC Immune and now being developed by Genentech, a Roche Group company. It was designed to target all forms of beta-amyloid molecules, the hallmark of Alzheimer’s, and has been evaluated for the treatment of prodromal (early) to mild forms of the disease. The antibody was also designed to minimize inflammation in the brain, which may lead to magnetic resonance imaging (MRI) abnormalities, coll
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *